Importance
of Monitoring

Regular monitoring is critical to identify and manage morbidities1–6

Thalassaemia International Federation guidelines recommend frequent monitoring of patients with thalassemia to identify and manage the development of morbidities and assess QOL*

Morbidities associated with all types of thalassemia can include1-6:

  • Pulmonary hypertension
  • Liver disease
  • Extramedullary hematopoiesis
  • Iron overload
  • Thrombotic disease
  • Endocrine and bone disease
  • Heart disease
  • Gallstones
  • Leg ulcers

QOL=quality of life.

Leading thalassemia specialists† recommend assessing quality of life as part of a long-term management plan for all patients with thalassemia.1-3,5

Clock representing daily activities

Daily activities

Barbell image

Physical health

Figure of human head with emphasis on the mind to represent emotional well-being

Emotional well-being

Person stretching

Functional well-being

†A Steering Committee of leading physicians was convened by Agios, and the physicians were compensated by Agios for their time.

Rethink patient care with long-term monitoring

Access our comprehensive Thalassemia Monitoring Guide to support regular assessments for your non–transfusion-dependent patients with thalassemia.

Download the HCP monitoring guide
Lightbulb with question mark representing info

With no medications available for all thalassemia patients that address both ineffective erythropoiesis and chronic hemolysis, regular monitoring is critical to identify and manage the development of morbidities.1‑3,5,6

Helpful resources for your practice and patients

Resources

Stay ahead in thalassemia care with the latest research and resources

Connect With Us

*Agios Pharmaceuticals provided partial support for the development and distribution of these guidelines through an unrestricted medical grant. The funding source played no role in the guideline process, including no role in the conception of the guidelines, the guidelines development process at any stage, the selection of the guideline working groups, the design, reporting, or implementation of the guidelines, or the guideline books and their review process. No representative from the funding source was invited to or present at any guideline planning or consensus meeting.

References:

1. Amid A et al, eds. Guidelines for the Management of α-Thalassaemia. Thalassaemia International Federation; 2023. 2. Taher AT et al. Guidelines for the Management of Non–Transfusion-Dependent β-Thalassaemia. 3rd ed. Thalassaemia International Federation; 2023. 3. Cappellini MD et al, eds. 2021 Guidelines for the Management of Transfusion Dependent Thalassemia (TDT). 4th ed. Thalassaemia International Federation; 2021. 4. Kwiatkowski JL. Guidelines for Managing Transfusion Therapy for Thalassemia. Cooley’s Anemia Foundation. May 31, 2018. Accessed December 20, 2024. https://www.thalassemia.org/thalassemia-management-checklists-now-available-download/ 5. Musallam KM et al. Blood Rev. 2024;64:101165. doi:10.1016/j.blre.2023.101165 6. Taher AT et al. N Engl J Med. 2021;384(8):727-743. doi:10.1056/NEJMra2021838